Mixed News for Neurocrine: Strong TD Data for INGREZZA, Caution on Vykat XR
Neurocrine reports strong KINECT-PRO results for INGREZZA in tardive dyskinesia quality of life, while experts flag safety risks for Vykat XR.
/ 3 items
#NBIX↓
Neurocrine Stock Weak Despite Strong Q2 Beat and Raise; Analysts Call Dip “Overdone”
Neurocrine reported $959M Q2 revenue (+39%) and raised Ingrezza guidance. Stock fell on short-term concerns, but analysts call the dip overdone and raise targets.
Neurocrine Expands Rare Disease Portfolio with $2.9B Soleno Buy
Neurocrine will buy Soleno for $2.9B, adding VYKAT XR, the first drug for extreme hunger in rare Prader-Willi syndrome.